Pseudoprolongation of the Prothrombin Time During Treatment with Recombinant Factor VIIa for Bleeding in a Patient with a Spontaneous Factor VIII Inhibitor

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa; a multicentre study.Thromb Haemost. 1997;78:1436–1437.

    Google Scholar 

  2. 2.

    Shirahata A, Kamiya T, Takamatsu J, et al. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.Int J Hematol. 2001;73:517–525.

    Article  PubMed  CAS  Google Scholar 

  3. 3.

    Macik BG, Lindley CM, Lusher J, et al. Safety and initial efficacy of three dose levels of recombinant activated factor VII (rVIIa): results of a phase I study.Blood Coagul Fibrinolysis. 1993;4:521–5277.

    Article  PubMed  CAS  Google Scholar 

  4. 4.

    Carr ME, Martin EJ, Carr SL. Delayed, reduced and inhibited thrombin production reduces platelet contractile force and results in weaker clot formation.Blood Coagul Fibrinolysis. 2002;13:193–1977.

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    Friederich PW, Levi M, Bauer KA, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.Circulation. 2001;103:2555–2559.

    Article  PubMed  CAS  Google Scholar 

  6. 6.

    Smith LG, Kitchens CS. Pseudo-prolongation of the partial thromboplastin time.Am J Clin Pathol. 1983;80:750–752.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Konle BA. Clinical use and laboratory monitoring of recombinant factor VIIa (NovoSeven“). Presented at: Hemostasis and Thrombosis Update 2001; April 26-28, 2001; Temple University School of Medicine, Philadelphia, Pa.

    Google Scholar 

  8. 8.

    Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.Haemophilia. 2001;7:517–522.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Marcus E. Carr or Jan G. Kuhn or Erika J. Martin or Ann R. Tidwell or Maura K. Hagane.

About this article

Cite this article

Carr, M.E., Kuhn, J.G., Martin, E.J. et al. Pseudoprolongation of the Prothrombin Time During Treatment with Recombinant Factor VIIa for Bleeding in a Patient with a Spontaneous Factor VIII Inhibitor. Int J Hematol 77, 308–309 (2003). https://doi.org/10.1007/BF02983792

Download citation

Keywords

  • Thrombin
  • Prothrombin Time
  • Recombinant Factor VIIa
  • NovoSeven
  • FVIII Inhibitor